Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,608.50
Bid: 1,609.50
Ask: 1,610.00
Change: 9.50 (0.59%)
Spread: 0.50 (0.031%)
Open: 1,601.50
High: 1,616.50
Low: 1,598.50
Prev. Close: 1,599.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET PULSE-McDonald's, Apple, Model N, Neurocrine, HD Supply, AMD

Tue, 10th Sep 2013 12:29

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s)

Sept. 10 (Reuters) - Some U.S. stocks to watch on Tuesday:

FUTURES CLIMB ON ROSY CHINA DATA, EASING SYRIA FEARS

U.S. stock index futures rose, putting the S&P 500 on trackfor a sixth day of gains, following another batch of rosyeconomic data out of China and as expectations eased about aWestern military strike against Syria. S&P 500 futures were up 0.65 percent, Dow Jones industrial average futures were up 0.62 percent, and Nasdaq 100 futures wereup 0.7 percent.

** APPLE INC, Monday close $506.17, up 0.5 pctpremarket

Apple is expected to introduce a cheaper version of theiPhone on Tuesday, bringing one of the industry's costliestsmartphones within reach of the masses in poorer emergingmarkets.

** MCDONALD'S CORP, Monday close $96.45, up 1 pctpremarket

The fast food chain reported a better-than-expected 1.9percent rise in global sales at established restaurants inAugust, boosted by stronger sales in Europe.

** ADVANCED MICRO DEVICES INC, Monday close $3.69,up 2 pct premarket

The chipmaker, targeting new markets as personal computersales decline, unveiled chips designed to run slot machines,factory robots, airport signs, medical equipment and otherdevices.

** MODEL N INC, Monday close $14.73, down 38 pctpremarket

The revenue management software maker forecast revenue forthe year ending September 2014 below analysts' estimates onMonday. Raymond James, Stifel Nicolaus and JPMorgan cut their ratings on the stock on Tuesday.

Analysts at Stifel said the company did not clearlyarticulate a plan to cut expenses. Raymond James analysts said areturn to revenue growth could be delayed well into 2015 unlessthe company quickly improved sales execution.

** NEUROCRINE BIOSCIENCES INC, Monday close $16.70,down 28 pct premarket

The company said on Monday that a lower dose of itsexperimental drug to treat a rare movement disorder did not meetthe main goal of a mid-stage clinical study. Cowen and Co cut its price target on the stock to $19 from $20while MKM Partners cut its target to $13.50 from $17.00 andOppenheimer to $15 from $19.

** HD SUPPLY HOLDINGS INC, Monday close $24.74, down9.5 pct premarket

The construction products supplier reported a widerquarterly loss for the second quarter due to expenses associatedwith debt restructuring. The company also forecast fiscal 2013results below analysts' estimates.

** STARWOOD PROPERTY TRUST INC, Monday close$25.04, down 4 pct premarket

The company, which finances and manages commercial mortgageloans, said it was offering 25 million shares in an underwrittenpublic offering.

** L&L ENERGY INC, Monday close $2.89, up 15 pctafter market

The coal miner's first-quarter profit more than doubled asproduction was boosted by the acquisition of two mines in Chinain November. Production rose 54 percent to 228,000 tons in thequarter.

** FIVE BELOW INC, Monday close $41.04, up 14 pctafter market

The specialty value retailer reported better-than-expectedresults for the second quarter due to a 6.6 percent increase insame-store sales. The company also raised its full-year earningsand revenue forecast.

** PVH CORP, Monday close $132.11, down 4.4 pctafter market

The maker of Calvin Klein and Tommy Hilfiger clothes gave athird-quarter sales and profit forecast that was below analysts'estimates. The company characterized the global environment as"challenging".

** BLACKBERRY LTD, Monday close $11.53, down 4 pctpremarket

The Canadian company's biggest shareholder has approachedseveral large Canadian investment funds about forging a deal totake the smartphone maker private, but the proposal is still "anairy-fairy, 'what if' kind of thing," according to a source withdirect knowledge of the situation.

** GLAXOSMITHKLINE PLC, Monday close $50.46, down 1pct premarket

The threat of generic copies of the company's best-sellinglung drug Advair finally making it to the market in the UnitedStates hit confidence in the drugmaker.

** MICROSOFT CORP, Monday close $31.65, up 1 pctpremarket

At least three of the top 20 investors in the company want aturnaround expert to succeed Steve Ballmer as chief executive.They have urged the technology giant's board to consider FordMotor Co Chief Executive Alan Mulally and ComputerSciences Corp Chief Executive Mike Lawrie for the job,several sources familiar with the matter said. (Compiled by Varun Aggarwal; Editing by Kirti Pandey)

More News
21 Jun 2023 09:19

GSK unveils positive trial results for vaccine against RSV

(Sharecast News) - GSK unveiled unveiled successful third phase clinical trial results for its Arexvy vaccine against respiratory syncytial virus in older adults.

Read more
21 Jun 2023 08:20

TOP NEWS: GSK reports positive data for RSV Arexvy vaccine

(Alliance News) - GSK PLC on Wednesday reported positive data for Arexvy, its respiratory syncytial virus vaccine for older adults.

Read more
20 Jun 2023 17:20

Miners, oil drag London stocks lower after modest China rate cut

Miners down as metal prices fall on strong dollar, China worries

*

Read more
20 Jun 2023 08:33

Lab crunch: British science has nowhere to go

OXFORD, England, June 20 (Reuters) - For Ros Deegan, the thrill of raising $100 million to expand a biotech firm among the dreaming spires of Oxford was soon tempered: unable to find a bigger laboratory, she routinely had to work at home.

Read more
16 Jun 2023 17:01

LONDON MARKET CLOSE: FTSE 100 ends a week of rate decisions higher

(Alliance News) - Stocks in London ended largely higher on Friday, following a busy week centred on the interest rate decisions of three major central banks.

Read more
16 Jun 2023 11:59

GSK cancer drug delay by FDA not "necessarily a red flag"

(Alliance News) - GSK PLC must gain approval for its "centrepiece" cancer drug momelotinib to validate its mergers & acquisitions pipeline but the extension of its review period in the US does not automatically spell trouble, according to analysis from Shore Capital on Friday.

Read more
16 Jun 2023 07:47

FDA extends review period of GSK blood cancer drug momelotinib

(Sharecast News) - GSK said on Friday that the US Food and Drug Administration has extended the review period of its new drug application for momelotinib, which is used to treat a blood cancer called myelofibrosis.

Read more
16 Jun 2023 07:42

IN BRIEF: GSK says FDA extending review period for blood cancer drug

GSK PLC - Brentford, England-based pharmaceutical company - Says US Food & Drug Administration has extended the review period of the new drug application for momelotinib by three months. Extension aims to provide time to review recently submitted data. The extended action date is September 16. Momelotinib uses "novel mechanism of action" to treat myelofibrosis, a rare blood cancer, as well as progressive anaemia which characterises the disease. Myelofibrosis affects approximately 25,000 US patients. The drug is not currently approved in any markets. GSK says it is "confident in the momelotinib NDA and looks forward to working with the FDA as they finalise their review."

Read more
9 Jun 2023 06:53

AstraZeneca hails RSV drug nirsevimab recommendation by FDA committee

(Alliance News) - AstraZeneca PLC on Thursday said that a US Food & Drug Administration committee unanimously recommended its antibody nirsevimab.

Read more
8 Jun 2023 12:09

London "still attractive" place to list, as IPO activity trickles back

(Alliance News) - A recent revival of initial public offerings in London's equity markets is encouraging evidence that the city still holds appeal on the global stage, analysts contended.

Read more
7 Jun 2023 09:22

EU approves its first vaccine for common respiratory virus RSV

June 7 (Reuters) - European regulators have approved the region's first vaccine for respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually.

Read more
7 Jun 2023 09:10

LONDON MARKET OPEN: Stocks head lower amid global growth fears

(Alliance News) - Stock prices in London opened in the red on Wednesday, as concerns about interest rate hikes and a global economic slowdown damped risk appetite.

Read more
7 Jun 2023 07:59

TOP NEWS: GSK's Arexvy is first EU-approved RSV jab for older adults

(Alliance News) - GSK PLC on Wednesday announced that its RSV vaccine Arexvy has become the first EU-backed vaccine against the respiratory syncytial virus for adults aged 60 and older.

Read more
7 Jun 2023 07:34

GSK gets European approval for RSV vaccine

(Sharecast News) - Pharmaceuticals giant GSK announced on Wednesday that the European Commission has granted authorisation for 'Arexvy' - an adjuvant respiratory syncytial virus (RSV) vaccine - for active immunisation to prevent RSV-caused lower respiratory tract disease (LRTD) in adults 60 and older.

Read more
6 Jun 2023 08:34

US FDA accepts GSK's licence application for cancer treatment Jemperli

(Alliance News) - GSK PLC on Tuesday said the US Food & Drug Administration accepted its supplemental biologics licence application for endometrial cancer treatment dostarlimab, or Jemperli, after it was granted priority review in September.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.